Best Diabetes Companies in England, United Kingdom
The 48 best Diabetes companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Apollo Therapeutics.
Ranked: Best Diabetes companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Apollo Therapeutics Developer of therapeutic programs based on biological and medical research | $372M | 35 mo ago | 11 | Richard Mason CEO | — | — | — |
| 2 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 43 mo ago | 18 | Giovanna Lombardi Co-Founder | TurbopackNode.jsSalesforce+13 | — | 1 partnership |
| 3 | WaveBreak Developer of small molecule therapeutics for neurological disorders | $60M | 28 mo ago | 51 | Bart Henderson CEO | — | — | — |
| 4 | Cellnovo Smart device for diabetic management | $48M | 111 mo ago | 92 | — | — | 90 patents Wireless wearable insulin pump systems with cartridge fault detection and handset communication | — |
| 5 | Mogrify Developer of regenerative medicine and cell therapies | $48M | 34 mo ago | 45 | Jose Polo Co-Founder | WordPressMySQLPHP+24 | 35 patents Cellular reprogramming and culture methods for regenerative therapy, notably cochlear hair cell generation. | — |
| 6 | Laverock Therapeutics Developer of next generation of programmable cell therapies 24Funding top 29%Moat top 42%Talent bottom 49%Global bottom 45% All 6 signals ▾Fundingtop 29% Moattop 42% Talentbottom 49% Globalbottom 45% Techbottom 43% Marketbottom 27% Funding: Raised $39.3M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $39M | 13 mo ago | 6 | David Venables CEO | WebflowGSAPcore-js+13 | — | — |
| 7 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 42 mo ago | 40 40 → 24 (-40%) | — | — | 204 patents Cyclodextrin and nanoparticle-based drug delivery systems for oncology and immunotherapy | 1 job opening · 1 expansion |
| 8 | PolyPhotonix Developer of photonic technology-based devices to treat diabetic retinotherapy | $10M | 54 mo ago | 8 | Richard Kirk CEO | — | 84 patents Phototherapy devices delivering specific light wavelengths for dermatological treatments | 1 launch |
| 9 | Exonate Developer of small molecule drugs for retinal vascular diseases | $4M | 91 mo ago | 17 17 → 16 (-6%) | — | — | 54 patents Small-molecule kinase inhibitors targeting ocular neovascular disease pathways | — |
| 10 | Zihipp Developer of drugs for obesity and diabetes treatment | $4M | 78 mo ago | 5 | — | — | — | — |
| 11 | Caura App-based auto insurance platform for individuals | $4M | 42 mo ago | 10 | — | WebflowBootstrapAmazon Web Services+14 | 3 patents Secure vehicle communication and control systems for automotive electronics | — |
| 12 | Biorasis Provider of a sensor platform for continuous glucose monitoring | $3M | 92 mo ago | 6 | — | — | — | — |
| 13 | Carbometrics Developer of glucose monitoring solution for diabetes | $3M | 27 mo ago | 13 | Anthony Davis Co-Founder & Director | — | 3 patents Carbohydrate detection sensors for analytical chemistry applications | — |
| 14 | PulseFlow Treatment for diabetic foot ulcers | $3M | 133 mo ago | 4 | — | — | — | — |
| 15 | Lein Applied Diagnostics Suite of measurement devices and solutions | $2M | 91 mo ago | 8 | — | — | 52 patents Medical optical measurement and alignment devices for in‑vitro diagnostic analysis | — |
| 16 | George Medicines Developer of single-pill combination treatments for cardiometabolic diseases | $2M | 48 mo ago | 2 | Mark Mallon CEO | WordPressMySQLPHP+19 | — | — |
| 17 | Quotient Diagnostics Develops Glycated haemoglobin (HbA1c) analysers to monitor the treatment of diabetes | $1M | 205 mo ago | 1 | Phillip Vessey Founder | — | 16 patents Patents concentrated in computing, sensing & instrumentation | — |
| 18 | Digostics Provider of home testing platforms for diabetes detection and management | $1M | 40 mo ago | 10 | Hugo Tewson Co-Founder | HubSpot CMS HubEnvoyGSAP+21 | — | 1 award |
| 19 | Luas Diagnostics Developer of sensors and connected app for diabetes management | $949K | 39 mo ago | 3 | — | — | — | — |
| 20 | Transdermal Diagnostics Provider of a needle-free continuous glucose monitoring device | $920K | 47 mo ago | 2 | Richard Guy Co-Founder | — | 5 patents Electrochemical transdermal sensors for continuous physiological analyte monitoring | — |
| 21 | Thermology Health Developer of thermal imaging platform for early detection of foot ulcers | $191K | 13 mo ago | — | Yuval Yashiv Chief Executive Officer | — | — | — |
| 22 | Adelie Health Provider of device and app for managing insulin dosage | $107K | 90 mo ago | 1 | Liam Morrow Founder | — | — | — |
Top 12 Diabetes companies in England
#1
Seed · Stevenage, England · founded 2021 · 6 employees$39.3Mraised▾
Developer of next generation of programmable cell therapies. The company utilizes gene editing induced gene silencing (GEiGS) technology, and its associated computational platform, to engineer induced pluripotent stem cell (iPSC) derived cell therapies.
- Jun 2025Seed$27.5M
- Sep 2023Seed$16.4M
- Aug 2022Seed$22.9M
#2
Series C · Cambridge, England · founded 2020 · 11 employees$371.5Mraised▾
Developer of therapeutic programs based on biological and medical research. The company's product pipeline include APL-9796: A first-in-class anti-ZIP12 monoclonal antibody for pulmonary hypertension, APL-045 and APL-10456, targeting neoplasms, immune disorders, and metabolic conditions via small molecules and antibodies.
- Sep 2023Series C$226.5M
- Jun 2021Series C$145M
#3
Series A · Cambridge, England · founded 2016 · 51 employees$60.3Mraised▾
Developer of small molecule therapeutics for neurological disorders. It offers drugs that targets the fleeting protein intermediates, the oligomers to treat Parkinson’s disease, Alzheimer’s disease, and ALS.
- Apr 2024Series A$16M
- Feb 2021Series A$2.1M
- Dec 2020Series A$14.8M
- Oct 2018Series A$23.1M
#4
Series B · London, England · founded 2019 · 18 employees$344.2Mraised▾
Developer of engineered regulatory T cell therapies for immune diseases. This clinical-stage organization focuses on modifying a patient's own regulatory T cells to restore immune balance. These therapies aim to address conditions involving autoimmunity, chronic inflammation, and organ transplant rejection by dampening immune responses and preventing tissue damage. The approach utilizes cellular engineering to regulate immune activity and manage severe inflammatory disorders.
- Jan 2023Series B$24.1M
- Mar 2022Series B$57.9M
- Nov 2021Series B$156M
- Dec 2020Series A$34.9M
#5
Series A · Cambridge, England · founded 2014 · 45 employees$47.8Mraised▾
Developer of regenerative medicine and cell therapies. It is developing a technology platform to treat diseases in the fields of regenerative medicine and cell therapies. They have developed a proprietary tailored cellular conversion technology platform (systematic big-data approach). It enables gene-regulatory data to identify the combination of transcription factors (in vitro) or small molecules (in vivo).
- Oct 2023Series A$10M
- May 2021Series A$17M
- Jan 2020Series A$1.1M
- Oct 2019Series A$16M
#6
Seed · Teddington, England · founded 2023$190.9Kraised▾
Developer of thermal imaging platform for early detection of foot ulcers. The platform uses temperature data to aid clinicians in early identification. It creates medically accurate temperature data, backed by published clinical studies. The platform is suitable for use in both clinical and at-home settings.
- 2025Seed$190.9K
#7
Public · Abingdon, England · founded 2000 · 40 employees$16Mraised▾
Provider of novel drug delivery technologies for the treatment of diseases. It develops a pipeline of product candidates in clinical and pre-clinical development for diseases such as diabetes, rare cancers including brain, ovarian, liver, and pancreatic cancer, and neurological/ophthalmologic conditions. It provides in-house technology platforms for sustained release to prolong and control the release of therapeutics over an extended period of time and dissolve insoluble drugs which can be converted into liquid form and can be treated for tumor patients.
- Feb 2023Post IPO$6M
- Aug 2020Post IPO$1M
- 2020Grant (prize money)$56.1K
- Oct 2019Post IPO$3M
#8
Seed · Bristol, England · founded 2018 · 13 employees$2.6Mraised▾
Developer of glucose monitoring solution for diabetes. The platform has developed the proprietary molecule biomimetic glucose binding molecule, It is the glucose-sensing molecule that can monitor the glucose level in diabetes patient.
- May 2024Seed$2.6M
#9
Seed · London, England · founded 2016 · 10 employees$4.2Mraised▾
App-based auto insurance platform for individuals. Their services include toll penalties, taxation, parking, and more. Its coverage includes windscreen cover, breakdowns, accidents, and more. It detects accidents and helps in claim processing. Their app is available for iOS devices.
- Jan 2023Conventional Debt$4.9M
- Jun 2021Seed$4.2M
- Dec 2019Grant (prize money)$56K
- Sep 2019Grant (prize money)$55K
#10
Deadpooled · London, England · founded 2002 · 92 employees$48.4Mraised▾
CellNovo provides a set of devices for diabetes management - mobile connected micropump, mobile touchscreen controller, blood glucose meter and a mobile app. Patients get to track their exercises with the in-built sensor in micropump, which also senses the influence of activity on blood glucose level; and later delivers the necessary amount of insulin. Patients can also share the recorded information, real-time, with their doctors and family, using the online portal. Attempted an IPO in July'15.
- May 2017Conventional Debt$5.5M
- Feb 2016Grant (prize money)$1.2M
- Feb 2011Series B$48.4M
#11
Series A · Sedgefield, England · founded 2008 · 8 employees$10Mraised▾
Developer of photonic technology-based devices to treat diabetic retinotherapy. The company develops non-invasive sleep masks that uses Organic Light-Emitting Devices (OLEDs), based on electroluminescence in certain organic molecules and polymers for the treatment for Diabetic Retinopathy and Diabetic Macular Oedema.
- Jan 2022Series A$10M
#12
Seed · Didcot, England · founded 2017 · 10 employees$1.1Mraised▾
Provider of home testing platforms for diabetes detection and management. The company's platforms offer accuracy comparable to clinic tests, eliminating staffing needs and laboratory delays. These platforms facilitate more extensive testing, faster results, and earlier clinical intervention. The company focuses on developing testing platforms designed for the detection of all types of diabetes.
- Apr 2023Seed$73K
- Dec 2021Seed$854.2K
- Feb 2020Seed$209.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.